Antiplatelet Strategy after Abbreviated Dual-antiplatelet therapy following New generation coronary stents implantatio
Not Applicable
Recruiting
- Conditions
- Diseases of the circulatory system
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3744
Inclusion Criteria
1. Patients = 19 years-old.
2. Patients who received zotarolimus-eluting stents (Onyx family) implantation for ischemic heart disease
3. Provision of informed consent
Exclusion Criteria
1. Patients = 85 years-old.
2. Acute myocardial infarction.
3. Left main bifurcation lesion requiring 2-stent technique.
4. Pregnant women or women with potential childbearing.
5. Life expectancy < 1 year.
6. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator.
7. Inability to understand or read the informed consent.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method et advese clinical outcomt (NACE, composite of all-cause death, myocardial infarction, stroke and major bleeding (BARC 2, 3 or 5))
- Secondary Outcome Measures
Name Time Method Each components of NACE (all-cause death, myocardial infarction, stroke and major bleeding (BARC 2, 3 or 5));Total ischemic event (all-cause death, myocardial infarction, stroke);Cardiovascular death (Defined as any death not due to any other apparent cause, such as cancer, infection or trauma);Stent thrombosis (including definite and probable stent thrombosis);Target vessel revascularization (Revascularization of vessels treated at the time of study enroll);Target lesion revascularization (Revascularization of lesions treated at the time of study enroll)